Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Zenas Biopharma Inc (NASDAQ: ZBIO) was $18.94 for the day, down -2.67% from the previous closing price of $19.46. In other words, the price has decreased by -$2.67 from its previous closing price. On the day, 0.85 million shares were traded. ZBIO stock price reached its highest trading level at $19.88 during the session, while it also had its lowest trading level at $18.65.
Ratios:
Our analysis of ZBIO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.23 and its Current Ratio is at 5.23.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Wedbush on March 20, 2025, initiated with a Outperform rating and assigned the stock a target price of $35.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $19.
On December 16, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.H.C. Wainwright initiated its Buy rating on December 16, 2024, with a $30 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 18 ’25 when MOULDER LEON O JR bought 25,000 shares for $6.67 per share. The transaction valued at 166,750 led to the insider holds 266,155 shares of the business.
Xiao Ting bought 10,000 shares of ZBIO for $77,600 on Feb 07 ’25. The Director now owns 47,000 shares after completing the transaction at $7.76 per share. On Dec 04 ’24, another insider, MOULDER LEON O JR, who serves as the Chief Executive Officer of the company, bought 45,000 shares for $9.98 each. As a result, the insider paid 449,100 and bolstered with 241,155 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZBIO now has a Market Capitalization of 797569344 and an Enterprise Value of 525298336. For the stock, the TTM Price-to-Sale (P/S) ratio is 53.17 while its Price-to-Book (P/B) ratio in mrq is 3.33. Its current Enterprise Value per Revenue stands at 35.02 whereas that against EBITDA is -2.779.
Stock Price History:
The Beta on a monthly basis for ZBIO is -2.09, which has changed by 0.01882732 over the last 52 weeks, in comparison to a change of 0.1653893 over the same period for the S&P500. Over the past 52 weeks, ZBIO has reached a high of $26.25, while it has fallen to a 52-week low of $5.83. The 50-Day Moving Average of the stock is 14.04%, while the 200-Day Moving Average is calculated to be 73.84%.
Shares Statistics:
ZBIO traded an average of 192.51K shares per day over the past three months and 325750 shares per day over the past ten days. A total of 42.09M shares are outstanding, with a floating share count of 10.31M. Insiders hold about 75.52% of the company’s shares, while institutions hold 35.90% stake in the company. Shares short for ZBIO as of 1756425600 were 5760485 with a Short Ratio of 29.92, compared to 1753920000 on 5225303. Therefore, it implies a Short% of Shares Outstanding of 5760485 and a Short% of Float of 20.080000000000002.
Earnings Estimates
. The current market rating for Zenas Biopharma Inc (ZBIO) reflects the collective analysis of 2.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.17, with high estimates of $1.55 and low estimates of -$1.2.
Analysts are recommending an EPS of between $1.77 and -$4.47 for the fiscal current year, implying an average EPS of -$1.35. EPS for the following year is -$5.0, with 2.0 analysts recommending between -$4.76 and -$5.24.
Revenue Estimates
A total of 6 analysts have provided revenue estimates for ZBIO’s current fiscal year. The highest revenue estimate was $160M, while the lowest revenue estimate was $10M, resulting in an average revenue estimate of $35M. In the same quarter a year ago, actual revenue was $5M
